The title implies that the combination treatments of DCVax with the interleukin and PD1/PDL1 (keytruda) adjuvant, and the anecdotal comments regarding higher percentages of OS extended observations.
DCVax is the common component of the combo treatments and appears to play an SOC role in the combo research and trials!
Imo the odds are the presentation enhances the DCVax case.
News 
Market Data 
Discover 
